Equity · Healthcare
INO
Inovio Pharmaceuticals, Inc. · NasdaqCM
The line runs $1.11 on 11 June through $1.43 on 4 September, on a scale from $0.50 to $1.50. Days the market did not trade hold the previous close, flat.
The chart above plots the price of INO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 60 sessions over that window: $1.11 on 11 June 2026 through $1.43 on 4 September 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026
INO insider trades
INO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 20 May 2026.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.
INO reported financials
INO reported revenue of $65K for the fiscal year ended 31 Dec 2025. Net income over the same period was −$84.9M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
INO earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
INO institutional holders
5 of the 45 institutional funds we track reported a INO position for the quarter ended 30 Jun 2026 — a combined $4.4M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
INO fails-to-deliver
On 14 Aug 2026, 2,190,601 shares of INO failed to deliver (about $2.0M) — the latest of 12 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data